What is HC Wainwright’s Estimate for KALV FY2029 Earnings?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Stock analysts at HC Wainwright reduced their FY2029 EPS estimates for KalVista Pharmaceuticals in a research report issued on Friday, December 6th. HC Wainwright analyst A. Fein now anticipates that the specialty pharmaceutical company will post earnings of $1.24 per share for the year, down from their prior estimate of $1.36. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($2.70) per share.

A number of other research analysts also recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $9.44 on Monday. The stock has a market cap of $466.52 million, a PE ratio of -2.59 and a beta of 0.85. The stock’s fifty day moving average is $10.81 and its two-hundred day moving average is $11.80. KalVista Pharmaceuticals has a 1-year low of $7.39 and a 1-year high of $16.88.

Insiders Place Their Bets

In related news, insider Paul K. Audhya sold 8,077 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares in the company, valued at $872,282.74. This represents a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the transaction, the chief executive officer now directly owns 266,598 shares in the company, valued at $2,468,697.48. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,291 shares of company stock valued at $304,086. 10.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its holdings in shares of KalVista Pharmaceuticals by 4.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after buying an additional 944 shares during the last quarter. HighVista Strategies LLC grew its stake in shares of KalVista Pharmaceuticals by 4.5% in the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock valued at $386,000 after purchasing an additional 1,432 shares during the last quarter. ClariVest Asset Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 2.8% in the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock valued at $673,000 after purchasing an additional 1,535 shares during the period. Nicholas Investment Partners LP raised its stake in shares of KalVista Pharmaceuticals by 0.9% during the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock worth $2,172,000 after purchasing an additional 1,714 shares during the last quarter. Finally, nVerses Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals during the second quarter worth $25,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).